BC Week In Review | Oct 19, 2015
Clinical News

IV finafloxacin: Additional Phase II data

Additional data from 193 patients hospitalized with cUTI and pyelonephritis in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met...
BC Week In Review | Oct 19, 2015
Clinical News

Oral finafloxacin: Additional Phase II data

Additional data from 193 patients hospitalized with cUTI and pyelonephritis in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met...
BC Week In Review | Feb 2, 2015
Clinical News

Xtoro topical finafloxacin regulatory update

FDA approved an NDA from Novartis’ Alcon Inc. unit for topical Xtoro finafloxacin to treat acute otitis externa (swimmer’s ear) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus. Xtoro is a pH-activated fluoroquinolone...
BC Week In Review | Jan 19, 2015
Clinical News

Oral finafloxacin: Phase II data

Data from 193 patients with cUTI in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the primary endpoint of...
BC Week In Review | Jan 19, 2015
Clinical News

IV finafloxacin: Phase II data

Data from 193 patients with cUTI in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the primary endpoint of...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Jun 30, 2014
Clinical News

IV finafloxacin: Completed Phase II enrollment

MerLion completed enrollment in a double-blind, double-dummy, European Phase II trial comparing 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in...
BC Week In Review | Sep 2, 2013
Clinical News

IV and oral finafloxacin regulatory update

MerLion said FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for IV and oral finafloxacin to treat complicated intra-abdominal infections (cIAI), acute bacterial skin and skin structure infections (ABSSSI) and complicated urinary...
BC Week In Review | Dec 17, 2012
Clinical News

IV finafloxacin: Phase II started

MerLion began a double-blind, double-dummy, European Phase II trial to compare 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in up...
BC Week In Review | Dec 17, 2012
Clinical News

Oral finafloxacin: Phase II started

MerLion began a double-blind, double-dummy, European Phase II trial to compare 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in up...
Items per page:
1 - 10 of 64
BC Week In Review | Oct 19, 2015
Clinical News

IV finafloxacin: Additional Phase II data

Additional data from 193 patients hospitalized with cUTI and pyelonephritis in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met...
BC Week In Review | Oct 19, 2015
Clinical News

Oral finafloxacin: Additional Phase II data

Additional data from 193 patients hospitalized with cUTI and pyelonephritis in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met...
BC Week In Review | Feb 2, 2015
Clinical News

Xtoro topical finafloxacin regulatory update

FDA approved an NDA from Novartis’ Alcon Inc. unit for topical Xtoro finafloxacin to treat acute otitis externa (swimmer’s ear) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus. Xtoro is a pH-activated fluoroquinolone...
BC Week In Review | Jan 19, 2015
Clinical News

Oral finafloxacin: Phase II data

Data from 193 patients with cUTI in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the primary endpoint of...
BC Week In Review | Jan 19, 2015
Clinical News

IV finafloxacin: Phase II data

Data from 193 patients with cUTI in the mITT population of a double-blind, double-dummy, European Phase II trial showed that 5- and 10-day regimens of once-daily 800 mg finafloxacin each met the primary endpoint of...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Jun 30, 2014
Clinical News

IV finafloxacin: Completed Phase II enrollment

MerLion completed enrollment in a double-blind, double-dummy, European Phase II trial comparing 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in...
BC Week In Review | Sep 2, 2013
Clinical News

IV and oral finafloxacin regulatory update

MerLion said FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for IV and oral finafloxacin to treat complicated intra-abdominal infections (cIAI), acute bacterial skin and skin structure infections (ABSSSI) and complicated urinary...
BC Week In Review | Dec 17, 2012
Clinical News

IV finafloxacin: Phase II started

MerLion began a double-blind, double-dummy, European Phase II trial to compare 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in up...
BC Week In Review | Dec 17, 2012
Clinical News

Oral finafloxacin: Phase II started

MerLion began a double-blind, double-dummy, European Phase II trial to compare 3.2 mg/mL IV finafloxacin and 200 mg oral finafloxacin for 5 or 10 days vs. oral and IV ciprofloxacin for 10 days in up...
Items per page:
1 - 10 of 64